4.国外实验猴价格上涨了好多。我想问一下国内情况如何？公司在这方 面是否有优势，然后在优势之上获取更多的订单？ 答：投资者您好，国内的价格没有明显的波动，相关事件暂时未对公司 的业务产生明显影响。 证券代码：300149 证券简称：睿智医药 睿智医药科技股份有限公司投资者关系活动记录表 编号：2023-02 | 投资者关系活动 | □特定对象调研 □分析师会议 | | --- | --- | | 类别 | □媒体采访 ■业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 □其他 | | 参与单位名称及 | 睿智医药 年度业绩说明会采用网络远程方式进行，面向全体投资者 2022 | | 人员姓名 | | | 时间 | 2023 年 5 月 23 日 15:00-17:00 | | 地点 | 深圳证券交易所"互动易平台"http://irm.cninfo.com.cn"云访谈"栏目 | | 公司接待人员姓 | 睿智医药董事、首席执行官：张继国 | | 名 | 睿智医药独立董事：杨凌 | | | 睿智医药首席财务官：王奎 | | | 睿智医药董事会秘书：许剑 | | | 1.公司在上海临港小分 ...

证券代码：300149 证券简称：睿智医药 公告编号：2023-31 睿智医药科技股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 出席本次说明会的人员有：公司董事、首席执行官张继国先生，首席财务官 王奎先生，独立董事杨凌先生，董事会秘书许剑先生。 为充分尊重投资者、提升交流效率及针对性，现就公司本次说明会提前向投 资者公开征集问题。投资者可提前登录"互动易"平台（http://irm.cninfo.com.cn） "云访谈"栏目，进入公司 2022 年度业绩说明会页面进行提问，公司将在本次 说明会上对投资者普遍关注的问题进行交流回答。欢迎广大投资者积极参与本次 说明会。 特此公告。 睿智医药科技股份有限公司 董事会 2023 年 5 月 12 日 睿智医药科技股份有限公司（以下简称"公司"）于 2023 年 4 月 27 日在中国 证监会指定的创业板信息披露媒体披露了《2022 年年度报告》及其摘要。为了 让广大投资者能进一步了解公司 2022 年年度报告和经营情况，加强公司与投资 者的沟通互动，公司将于 ...

Financial Performance - The company's revenue for Q1 2023 was ¥268,658,644.91, a decrease of 30.45% compared to ¥386,301,922.70 in the same period last year[4] - The net profit attributable to shareholders for Q1 2023 was a loss of ¥28,566,911.66, representing a decline of 401.63% from a profit of ¥9,470,996.67 in Q1 2022[4] - The basic and diluted earnings per share for Q1 2023 were both -¥0.0574, a decline of 402.11% from ¥0.0190 in Q1 2022[4] - Total operating revenue for Q1 2023 was CNY 268,658,644.91, a decrease of 30.5% compared to CNY 386,301,922.70 in the same period last year[18] - Net profit for Q1 2023 was a loss of CNY 28,595,596.14, compared to a profit of CNY 9,416,742.22 in Q1 2022, marking a significant decline[19] - Earnings per share for Q1 2023 was CNY -0.0574, compared to CNY 0.0190 in the same quarter last year[20] Cash Flow - The net cash flow from operating activities was -¥20,654,400.58, a decrease of 159.11% compared to ¥34,944,776.30 in the previous year[4] - The company reported a net cash outflow from operating activities of CNY -20,654,400.58, contrasting with a net inflow of CNY 34,944,776.30 in the previous year[21] - Cash flow from investing activities showed a net inflow of ¥215,815,097.92, a significant increase of 663.05% compared to -¥38,329,695.69 in the previous year[8] - The net cash flow from investment activities was 215,815,097.92 CNY, compared to a negative cash flow of -38,329,695.69 CNY in the previous period[23] - Cash inflow from financing activities totaled 30,000,000.00 CNY, while cash outflow was 299,984,196.03 CNY, resulting in a net cash flow of -269,984,196.03 CNY[23] - The company incurred a cash outflow of 288,702,550.13 CNY for debt repayment during the financing activities[23] Assets and Liabilities - The total assets at the end of Q1 2023 were ¥3,482,725,233.96, down 8.92% from ¥3,823,897,141.71 at the end of the previous year[4] - The total liabilities decreased to CNY 1,130,773,989.50 from CNY 1,437,935,834.66, reflecting a reduction of approximately 21.3%[16] - Total current assets decreased to ¥869,398,720.68 from ¥1,280,359,412.36, representing a decline of about 32%[15] - Total current liabilities decreased to ¥588,480,406.09 from ¥732,030,937.52, a decline of approximately 19.6%[15] - Short-term borrowings decreased to ¥95,022,611.08 from ¥115,022,611.12, a decrease of about 17.4%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 27,692[9] - The largest shareholder, Beihai Baben Venture Capital Co., Ltd., holds 13.69% of shares, totaling 68,441,800 shares[9] Other Financial Metrics - The company reported non-recurring gains and losses totaling ¥4,101,157.00 for the period[5] - Research and development expenses for Q1 2023 were CNY 20,950,769.76, down 26.1% from CNY 28,398,046.08 in the previous year[18] - The company recorded investment income of CNY 3,280,955.00, significantly higher than CNY 440,243.17 in Q1 2022[19] - Other comprehensive income after tax for Q1 2023 was CNY -5,414,466.45, compared to CNY -858,641.86 in the same period last year[20] Future Outlook - The company plans to continue its market expansion and product development strategies in the upcoming quarters[10] Audit Status - The first quarter report was not audited[24]

希格玛会计师事务所(特殊普通合伙) Xigema Cpas(Special General Partnership) 关于新疆百花村医药集团股份有限公司 非公开发行股票项目反馈意见的回复 中国证券监督管理委员会: 根据贵会 2022年3月7日下发的《中国证监会行政许可项目审查一次反馈意 见通知书》(220241 号)(以下简称"《反馈意见》")的要求,我们在审慎调查的基 础上,就《反馈意见》的相关问题作出如下答复: 反馈意见 9: 申请人于 2016 年完成资产置出并置入华威医药 CRO 业务资产, CRO 业务收入为申请人报告期内最主要的收入来源。最近三年一期,申请人扣非归 母净利润分别-68,622.79 万元、731.11 万元、 -36,923.75 万元、595.78 万元, 其中 2020 年营业收入 8,453.04 万元。公司股票于 2021 年 4 月 1 日起被实施 "退市风险警示"。请申请人:(1)说明报告期内业绩大幅波动的主要原因,业绩 大亏与微利交替出现的原因及合理性,是否与同行业公司一致,是否存在操纵公 司业绩规避退市等情况;(2)结合上述情况说明申请人持续经营是否存在重大风 险, ...

Revenue and Profit - Revenue for Q3 2022 was CNY 345,340,861.01, a decrease of 17.00% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2022 reached CNY 66,807,165.81, an increase of 589.07% year-on-year[5] - The net profit excluding non-recurring gains and losses for Q3 2022 was CNY 62,564,174.47, up 1,497.54% from the previous year[5] - Total operating revenue for the current period is ¥1,032,237,378.52, a decrease of 18.14% compared to ¥1,261,483,497.11 in the previous period[22] - Net profit for the current period is ¥1,023,227,946.22, significantly up from ¥14,696,541.00 in the previous period, indicating a substantial increase[24] - Earnings per share (EPS) for the current period is ¥2.0542, compared to ¥0.0298 in the previous period, showing a remarkable growth[25] Assets and Liabilities - Total assets as of September 30, 2022, were CNY 4,704,447,163.36, reflecting an increase of 11.54% from the end of the previous year[5] - As of September 30, 2022, the total current assets amounted to ¥1,604,725,211.85, a significant increase from ¥687,744,820.18 at the beginning of the year, reflecting a growth of approximately 133%[19] - The total liabilities decreased to ¥1,667,990,232.50 from ¥2,228,514,640.12, a reduction of approximately 25%[20] - The company's long-term investments increased to ¥200,833,672.98 from ¥175,963,635.87, reflecting a growth of about 14.1%[20] - The total non-current assets were reported at ¥3,099,721,951.51, down from ¥3,529,846,706.50, indicating a decrease of about 12.2%[20] Cash Flow - Cash flow from operating activities for the year-to-date was negative CNY 64,380,653.93, a decrease of 124.56% compared to the previous year[15] - The cash inflow from financing activities was 226,000,000.00 CNY, compared to 433,558,281.11 CNY in the previous year[27] - The net cash flow from investment activities was 1,295,554,689.49 CNY, compared to a negative cash flow of -249,156,566.84 CNY in the previous year[27] - Cash and cash equivalents at the end of the period totaled 703,629,140.59 CNY, up from 305,332,809.78 CNY year-over-year[27] - The net increase in cash and cash equivalents for the period was 550,636,092.78 CNY, compared to 59,498,825.87 CNY in the previous year[27] Investment and Other Income - Investment income for the year-to-date was CNY 1,359,661,265.46, a significant increase of 27,953.66% year-on-year, primarily due to the disposal of subsidiaries[12] - The company reported an investment income of ¥1,359,661,265.46, a significant increase from ¥4,846,645.06 in the previous period[22] - Other comprehensive income after tax for the current period is ¥29,215,107.02, compared to a loss of ¥672,079.71 in the previous period[24] Equity and Return Metrics - The weighted average return on equity for Q3 2022 was 2.25%, an increase of 1.85 percentage points year-on-year[5] - The total equity attributable to shareholders increased to CNY 3,011,988,517.40, up 53.33% from the end of the previous year[5] - The company reported a total equity of ¥499,776,892.00, unchanged from the previous period[20] Research and Development - Research and development expenses decreased to ¥80,277,254.61 from ¥90,982,840.49, a reduction of 11.88%[22] Miscellaneous - The company has not disclosed any new product developments or market expansion strategies in the current report[18] - The company did not undergo an audit for the third quarter report[28] - The report was released by the board of directors on October 27, 2022[29]

Revenue and Profitability - Revenue for Q1 2022 was CNY 386.30 million, a decrease of 0.87% compared to CNY 389.71 million in the same period last year[4] - Net profit attributable to shareholders increased by 480.41% to CNY 9.47 million from CNY 1.63 million year-on-year[4] - Net profit excluding non-recurring items rose by 281.04% to CNY 8.19 million, compared to a loss of CNY 4.52 million in the previous year[4] - Basic and diluted earnings per share increased by 475.76% to CNY 0.019 per share from CNY 0.0033 per share year-on-year[4] - The company reported a net profit margin of approximately 4.0% for Q1 2022, compared to 3.8% in the previous year[22] - The net profit for the first quarter of 2022 was CNY 9,416,742.22, a significant increase compared to CNY 1,593,355.43 in the same period last year, representing a growth of approximately 490%[23] - Basic and diluted earnings per share were both CNY 0.019, up from CNY 0.003 in the previous year, marking a growth of 533%[24] Assets and Liabilities - Total assets at the end of Q1 2022 were CNY 4.22 billion, a slight decrease of 0.05% from CNY 4.22 billion at the end of the previous year[4] - Total assets decreased slightly to CNY 4,215,614,127.91 from CNY 4,217,591,526.68[19] - Total liabilities were CNY 2,223,042,149.89, a slight decrease from CNY 2,228,514,640.12[20] - Shareholders' equity increased to CNY 1,992,571,978.02 from CNY 1,989,076,886.56[20] Cash Flow - Cash flow from operating activities decreased by 46.26% to CNY 34.94 million from CNY 65.03 million in the same period last year[11] - The cash flow from operating activities was CNY 34,944,776.30, a decline from CNY 65,025,423.75, representing a decrease of about 46%[26] - The cash and cash equivalents at the end of the period were CNY 53,582,669.86, a decrease from CNY 285,075,716.31 at the end of the previous year[26] - The company incurred a total of CNY 115,633,226.13 in cash outflows from financing activities, compared to CNY 147,188,755.67 in the same period last year, indicating a reduction of about 21.5%[26] - The company’s cash flow from financing activities decreased by 250% to -CNY 95.63 million, mainly due to a reduction in bank borrowings[11] Operating Performance - Total operating revenue for Q1 2022 was CNY 386,301,922.70, a decrease of 0.1% compared to CNY 389,706,314.16 in the same period last year[22] - Total operating costs for Q1 2022 were CNY 368,984,885.99, down 6.4% from CNY 394,135,991.16 year-over-year[22] - Operating costs included CNY 233,431,931.86 in cost of goods sold, a decrease of 15.3% from CNY 275,727,777.91 in the previous year[22] - The total revenue from operating activities was CNY 342,149,405.36, down from CNY 415,774,844.21 in the previous year, indicating a decrease of approximately 17.6%[24] Accounts Receivable and Inventory - The company reported a significant increase in accounts receivable by 23.81% to CNY 414.98 million, primarily due to an increase in service fees receivable[8] - Accounts receivable increased to CNY 414,977,425.27 from CNY 335,165,521.71, representing a growth of 23.8%[18] - Inventory at the end of Q1 2022 was CNY 77,517,458.55, an increase of 12.5% from CNY 68,812,426.27 at the beginning of the year[18] Expenses - The company’s management expenses rose by 22.84% to CNY 67.84 million, mainly due to increased initial operating costs of the Jiangsu Innovation Biopharmaceutical platform[10] - Research and development expenses increased to CNY 28,398,046.08 from CNY 24,806,172.55, reflecting a year-over-year increase of about 23%[23] Investment Income - The company’s investment income decreased by 89.80% to CNY 440,243.17, primarily due to reduced investment returns from ShangPharma Capital LP[10] - The investment activities resulted in a net cash outflow of CNY 38,329,695.69, an improvement from a net outflow of CNY 89,865,489.00 in the previous year[26] Other Financial Metrics - The company reported a comprehensive income of CNY 8,558,100.36, compared to a loss of CNY 1,975,964.26 in the same quarter last year[24] - The company experienced a foreign exchange loss of CNY 858,641.86, compared to a loss of CNY 3,569,319.69 in the same quarter last year[24]

Financial Performance - The company reported a significant loss primarily due to a large goodwill impairment and an increase in period expenses [4]. - The company's total revenue for 2021 was ¥1,690,677,943.33, representing a 14.11% increase from ¥1,481,591,872.64 in 2020 [20]. - The net profit attributable to shareholders was -¥402,245,074.78, a decrease of 360.27% compared to a profit of ¥154,550,403.78 in 2020 [20]. - The net cash flow from operating activities was ¥378,219,891.25, up 10.22% from ¥343,160,357.56 in the previous year [20]. - The total assets at the end of 2021 amounted to ¥4,217,591,526.68, a 2.33% increase from ¥4,121,581,017.24 at the end of 2020 [20]. - The net assets attributable to shareholders decreased by 19.09% to ¥1,964,444,590.44 from ¥2,427,903,737.42 in 2020 [20]. - The basic earnings per share for 2021 was -¥0.81, a decline of 361.29% from ¥0.31 in 2020 [20]. - The weighted average return on equity was -18.40%, down 24.95% from 6.55% in 2020 [20]. - In Q4 2021, the company reported a net profit attributable to shareholders of -¥417,078,237.49, significantly impacting the annual results [22]. - The company reported a total revenue after deductions of ¥1,684,522,730.56 for 2021 [20]. Business Strategy and Focus - The company plans to focus on its core business to enhance its industry position and sustainable development capabilities [4]. - The company plans to divest its prebiotic business to focus on CRO/CDMO services, with the sale of Quantum High-Tech (Guangdong) Bio Co., Ltd. approved by shareholders [32]. - The company aims to expand its domestic market presence, optimizing its customer operation system to increase market share in China's rapidly growing pharmaceutical market [105]. - The company is advancing the construction of a 4500L capacity production base in Qidong, Jiangsu, to enhance its biopharmaceutical production capabilities [106]. - The company is actively pursuing market expansion strategies, including potential mergers and acquisitions to strengthen its market position [143]. Risks and Challenges - The company faces various risks, including a decline in service demand and potential failure in new technology development [5]. - Future plans and performance forecasts do not constitute commitments to investors, highlighting the need for risk awareness [5]. - The company faces risks related to declining demand for pharmaceutical R&D services, which could significantly impact its business if industry growth slows [109]. - The company acknowledges the risk of goodwill impairment from its acquisition of Shanghai Ruizhi, emphasizing the need for effective resource integration to mitigate this risk [115]. - The company faces risks related to obtaining necessary qualifications for drug research and production, which could lead to sanctions or operational interruptions if not secured [117]. Governance and Management - The audit report issued by Ernst & Young included a paragraph on significant uncertainties regarding the company's ability to continue as a going concern [4]. - The company’s financial report has been confirmed as true, accurate, and complete by its management team [3]. - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with governance standards and effective decision-making [127]. - The company has established a performance evaluation and incentive mechanism to align executive compensation with company performance, promoting long-term stability [131]. - The company has implemented measures to ensure transparency and equal access to information for all shareholders [132]. Research and Development - The company has developed a database of 8 million small molecules for virtual screening, enhancing its drug design capabilities [36]. - The company has submitted a patent application for a new GalNAc drug delivery molecule, expanding its capabilities in peptide chemistry [36]. - The company has developed a series of advanced technology platforms for drug discovery, including CRISPR target validation and gene-encoded compound libraries [60]. - The company’s R&D expenses reached CNY 124,652,569.11, a 73.91% increase compared to the previous year, driven by investments in technology platform innovation [78]. Environmental Responsibility - The company has established a comprehensive environmental protection management system, with specific departments responsible for executing environmental protection tasks [195]. - The company actively promotes green chemistry initiatives, focusing on reducing the environmental impact of chemical use from the source [196]. - The company conducts annual soil and groundwater testing, with reports submitted to the local ecological environment bureau [193]. - The company has installed online monitoring systems for wastewater and air emissions, ensuring real-time data transmission to the Shanghai Environmental Protection Bureau [192]. - The company has made significant investments in environmental protection, resulting in improved management and technical levels [194]. Shareholder Relations - No cash dividends or stock bonuses will be distributed to shareholders [6]. - The company reported a total cash dividend amount of ¥20,443,281.30 from share repurchases, with no cash dividends or stock bonuses distributed to shareholders for the fiscal year 2021 [169]. - The company incurred losses for the fiscal year 2021 and decided not to distribute profits to ensure sufficient funding for long-term development [170]. - The company has a clear strategy for maintaining operational independence from its controlling shareholders [135].

Financial Performance - The company's revenue for Q3 2021 was ¥416,090,491.65, representing a 4.25% increase compared to the same period last year[4] - The net profit attributable to shareholders decreased by 77.14% to ¥9,695,301.07, while the net profit excluding non-recurring gains and losses dropped by 89.20% to ¥3,916,277.66[4] - In the first three quarters of 2021, the company achieved a total revenue of RMB 1,261.48 million, representing a year-on-year growth of 17.97%[20] - The net profit attributable to shareholders for the first three quarters of 2021 was RMB 14.83 million, a decline of 82.19% year-on-year[21] - In Q3 2021, the net profit attributable to shareholders was RMB 9.70 million, down 77.14% year-on-year, primarily due to increased labor costs and initial costs from the commercial production project in Qidong, Jiangsu[21] - The total comprehensive income for Q3 2021 was CNY 14,024,461, compared to CNY 73,509,840 in Q3 2020, reflecting a decline of 81.0%[31] - The basic and diluted earnings per share for Q3 2021 were both CNY 0.03, down from CNY 0.17 in Q3 2020[31] Assets and Liabilities - Total assets increased by 16.94% to ¥4,819,831,851.24 compared to the end of the previous year[4] - Total liabilities rose to ¥2,408,610,396.23 from ¥1,669,193,302.07, marking an increase of about 44%[27] - Total assets amounted to approximately ¥4.12 billion, with a significant increase to ¥4.71 billion after adjustments[38] - Current assets totaled approximately ¥919.88 million, while non-current assets reached approximately ¥3.20 billion[38] - Total liabilities were approximately ¥1.67 billion, with non-current liabilities accounting for about ¥881.59 million[38] Cash Flow - The cash flow from financing activities decreased by 65.68% to ¥47,288,299.37, primarily due to reduced net borrowings and dividend payments during the reporting period[12] - Cash flow from operating activities generated a net amount of CNY 262,135,150.87, an increase of 24.7% from CNY 210,247,510.40 in the previous year[34] - Cash and cash equivalents as of September 30, 2021, were ¥318,619,661.89, compared to ¥259,121,396.09 at the end of 2020, indicating a growth of about 23%[25] - Cash and cash equivalents at the end of Q3 2021 totaled CNY 305,332,809.78, up from CNY 236,978,183.67 at the end of Q3 2020[34] - Investment activities resulted in a net cash outflow of CNY 249,156,566.84, an improvement from a net outflow of CNY 308,190,992.18 in the same period last year[34] Research and Development - Research and development expenses surged by 99.53% to ¥90,982,840.49, indicating increased investment in pharmaceutical R&D and production outsourcing services[11] - Research and development expenses increased significantly to CNY 90,982,840, up 99.5% from CNY 45,599,044 in the same period last year[30] Shareholder Information - The company’s total equity attributable to shareholders decreased by 1.69% to ¥2,386,874,098.93 compared to the end of the previous year[4] - The company’s equity attributable to shareholders decreased from ¥2,427,903,737.42 to ¥2,386,874,098.93, a decline of about 2%[27] - The company’s major shareholder, Yunnan Baben Health Industry Co., Ltd., holds 15.28% of the shares, with 76,342,300 shares pledged[16] - The top ten shareholders collectively hold significant stakes, with the largest shareholder having 15.28% of the total shares[16] Operational Performance - Total operating revenue for the period reached ¥1,261,483,497.11, an increase of approximately 18% compared to ¥1,069,362,339.50 in the previous period[29] - Total operating costs amounted to ¥1,261,078,461.21, up from ¥985,350,121.86, reflecting a significant rise in operational expenses[29] - The company reported a significant increase in sales revenue, with cash received from sales reaching CNY 1,315,426,854.98, compared to CNY 1,065,140,303.11 in the previous year, marking a growth of 23.5%[32] Inventory and Receivables - Accounts receivable decreased to ¥360,671,069.79 from ¥384,470,762.02, showing a reduction of approximately 6%[25] - The company reported a decrease in inventory from ¥54,807,328.19 to ¥64,320,928.92, indicating a change in inventory management strategy[25] - Inventory was valued at approximately ¥54.81 million, suggesting effective inventory control[37] Management and Future Outlook - The company plans to enhance its compensation incentive system to address rising labor costs[21] - The micro-ecological health business is expected to continue growing due to increased market share and customer base[21] - The company experienced a significant increase in management expenses, which rose to CNY 193,356,100.55, compared to CNY 166,708,677.26 in the previous year, reflecting a rise of 15.9%[30] Compliance and Audit - The company has not yet audited the third-quarter report, which may affect the reliability of the financial data presented[40] - The company is in compliance with the new leasing standards, which may impact future financial reporting[40]

Financial Performance - The company reported a significant increase in revenue for the first half of 2021, with a total revenue of CNY 500 million, representing a 25% year-over-year growth[13]. - The company's operating revenue for the reporting period was ¥845,393,005.46, representing a 26.14% increase compared to ¥670,228,150.02 in the same period last year[19]. - The net profit attributable to shareholders was ¥5,137,861.60, a decrease of 87.43% from ¥40,888,811.58 in the previous year[19]. - The net cash flow from operating activities increased by 46.49% to ¥168,844,202.51, up from ¥115,256,353.71 in the same period last year[19]. - The company reported a total revenue of 1,252.45 million, representing a 7.71% increase compared to the previous period[138]. - The company's net profit attributable to ordinary shareholders was 30.65 million, a decrease of 14.64% from 35.91 million in the previous year[45]. - The company's total equity attributable to shareholders decreased to ¥2,073,501,986.14 from ¥2,148,885,818.22, a decline of approximately 3.5%[191]. Market Expansion and Strategy - The company has provided a positive outlook for the second half of 2021, projecting a revenue growth of 20% to 30%[13]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2022[13]. - The company is positioned as a leader in the domestic market for preclinical drug development services, serving over 2,300 global clients[35]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[192]. - The company is expanding its market presence, particularly in the biopharmaceutical sector, with strategic partnerships and investments[142]. Research and Development - New product development includes the launch of two innovative drug candidates, expected to enter clinical trials by Q4 2021[13]. - The company plans to invest CNY 200 million in new technology for drug development over the next two years[13]. - R&D investment surged by 170.27% to ¥58,522,126.45, reflecting the company's commitment to enhancing its research capabilities[59]. - The company has established a comprehensive end-to-end service capability for biopharmaceuticals, covering drug discovery to large-scale production[51]. - The company has delivered over 900 protein products to clients, showcasing its extensive capabilities in biopharmaceutical research and development[52]. Client and Revenue Segments - The CRO/CDMO segment generated revenue of ¥684,162,600, accounting for 81% of total revenue, with preclinical CRO services contributing ¥577,957,800, or 84% of the CRO/CDMO segment[27]. - The micro-ecological health segment achieved revenue of ¥161,600,900, representing 19% of total revenue[30]. - The company expanded its client base in the CRO segment, serving 698 clients in the first half of 2021, with 160 new clients contributing over 50 million yuan in revenue, a 29.5% increase year-on-year[41]. - The company has 55 small molecule CDMO service projects, with 42 in early stages and 10 in late clinical phases, indicating a robust project pipeline[42]. Financial Management and Investments - The company will not distribute cash dividends or issue bonus shares for the current fiscal year[5]. - The company has recognized significant goodwill from the acquisition of Shanghai Ruizhi, which may be at risk of impairment if future performance does not meet expectations[88]. - The company has a total approved guarantee amount of 139 million yuan, with an actual guarantee balance of 44.593 million yuan, representing 18.77% of the company's net assets[158]. - The company has made a total investment of 13.56 million USD in the pharmaceutical innovation fund as of June 30, 2021[142]. Risks and Challenges - The management highlighted risks including potential declines in service demand and challenges in core technology retention[4]. - The company faces risks from a potential decline in demand for pharmaceutical R&D services, which could significantly impact its business if industry growth trends reverse[84]. - The company has identified risks related to the loss of key scientific and management personnel, which could adversely affect service quality and business operations[85]. - The company is exposed to foreign exchange risks primarily related to USD and EUR, which could pressure profit margins if the RMB appreciates[90]. Environmental and Compliance - The company has established waste management protocols, including hazardous waste storage facilities, to comply with environmental regulations and ensure proper disposal of hazardous materials[106]. - The company has implemented an environmental self-monitoring program, including annual waste gas monitoring and quarterly wastewater and noise monitoring[116]. - The company emphasizes green chemistry initiatives to reduce environmental impact and improve synthesis efficiency[121]. - The company has maintained AAALAC certification for ten consecutive years, ensuring high standards in animal welfare for drug development[126]. Corporate Governance and Shareholder Information - The company has not distributed cash dividends or issued bonus shares during the reporting period, indicating a focus on reinvestment rather than immediate shareholder returns[103]. - The company has not engaged in any violations regarding external guarantees during the reporting period[131]. - The chairman of the company is currently under investigation but continues to perform his duties normally[134]. - The total number of ordinary shareholders at the end of the reporting period was 15,225[169].

Financial Performance - The company's revenue for Q1 2021 was ¥389,706,314.16, representing a 39.81% increase compared to ¥278,744,900.86 in the same period last year[8]. - Net profit attributable to shareholders was ¥1,631,770.54, a significant turnaround from a loss of ¥14,153,944.58, marking an increase of 111.53%[8]. - The net cash flow from operating activities reached ¥65,025,423.75, up 277.45% from ¥17,227,621.05 in the previous year[8]. - Basic and diluted earnings per share improved to ¥0.003 from a loss of ¥0.028, reflecting a 110.71% increase[8]. - The company achieved operating revenue of RMB 389.71 million in Q1 2021, representing a year-on-year increase of 39.81%[24]. - The net profit attributable to ordinary shareholders was RMB 1.63 million, marking a turnaround from a loss in the same period last year[24]. - The company reported a gross profit margin of approximately -1.1% for Q1 2021, compared to -5.9% in the previous year[43]. - The company experienced a total comprehensive loss of CNY 1.98 million in Q1 2021, compared to a loss of CNY 11.57 million in the same period last year[44]. Assets and Liabilities - Total assets at the end of the reporting period were ¥4,771,657,614.89, a 15.77% increase from ¥4,121,581,017.24 at the end of the previous year[8]. - The total liabilities increased to CNY 2,341,695,235.37 from CNY 1,669,193,302.07, reflecting a rise of approximately 40.2%[36]. - The company's current assets totaled CNY 942,292,294.06, compared to CNY 919,879,207.40 at the end of 2020, indicating a slight increase of about 2.5%[34]. - The total liabilities as of the end of Q1 2021 were CNY 955.25 million, compared to CNY 928.48 million at the end of the previous year[43]. - The company reported a decrease in accounts payable to CNY 99,485,992.11 from CNY 77,236,033.59, an increase of about 28.8%[36]. Shareholder Information - The total number of shareholders at the end of the reporting period was 16,002[12]. - The largest shareholder, Yunnan Baben Health Industry Co., Ltd., held 16.05% of the shares, amounting to 80,199,000 shares[12]. - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[13]. - The company repurchased 1,450,000 shares, accounting for 0.29% of the total share capital, with a total expenditure of RMB 20.44 million[27]. Research and Development - Research and development expenses increased by 181.12% to RMB 24.81 million, reflecting the company's commitment to enhancing R&D investment[21]. - The pharmaceutical R&D and production outsourcing business generated revenue of RMB 305.95 million, up 37.31% year-on-year[24]. - Research and development expenses increased to CNY 24.81 million in Q1 2021, up from CNY 8.82 million in the same period last year, reflecting a focus on innovation[43]. Cash Flow - Operating cash inflow from sales increased to ¥395,537,010.87, up from ¥256,847,435.91, representing a growth of 54.2%[49]. - Net cash flow from financing activities improved to ¥63,937,725.44, up from ¥37,742,319.47, reflecting an increase of 69.5%[51]. - The company reported a net increase in cash and cash equivalents of ¥39,241,732.40, compared to a decrease of ¥76,569,086.18 in the previous period[51]. - Cash outflow from investment activities totaled ¥192,581,927.93, down from ¥323,207,835.22, indicating a reduction of 40.5%[50]. Future Outlook - The company plans to continue its market expansion efforts and maintain focus on R&D to drive future growth[24].